Latigo Biotherapeutics files for Nasdaq IPO in non-opioid painkiller race
As seen on the 24/7 Wall St. homepage on July 17, 2026.
Pain relief biotech Latigo filed to go public as non-opioid painkillers become the race to watch on Wall Street, backed by Goldman Sachs and Jefferies.
Continue ReadingShow less
Latigo Biotherapeutics submitted its IPO registration with the SEC on July 17, 2026, proposing to list on Nasdaq under the ticker LTGO. Goldman Sachs and Jefferies are backing the offering, lending the deal a notable pedigree as investor appetite for the non-opioid pain relief space grows.
The filing places Latigo squarely in one of biotech's most closely watched competitive arenas right now — developing effective alternatives to opioid painkillers without the addiction risks that have made traditional pain management so controversial. A credible underwriter lineup often signals institutional confidence, though key deal terms including share count and price range have not yet been disclosed in the registration.
Sponsored
_________________________________
What's Your Number...?
Here's a question most people 5y from retirement can't answer: at your current savings rate, how much do you need, and how long will it actually last? A good advisor can put a date on that in a single meeting. SmartAsset's free quiz matches you with up to three fiduciary advisors serving your area, so you can get YOUR retirement number now (sponsor)
__________________________________________
Because the offering is still at the registered stage, investors should watch for an amended filing that fills in pricing details and use-of-proceeds disclosures before drawing conclusions about valuation or deal size.
Mentioned: LTGO